#biomanufacturing

‘Obscure’ Lampshades by  Biohm

Obscure is made of 100% coffee chaff and orange peel.

The lampshades begin their life as the peels of oranges after they have been juiced or the chaff of coffee beans after they had been roasted. 

They are then mixed with Biohm’s unique organic binder to create Orb, which can be pressed, moulded, extruded or 3D-printed.

Outta This World

Stem cells hold much hope for medicine as they can become a range of different cell types. Researchers in labs across the globe are studying the biology of these specialised cells and testing ways to turn them into cardiac cells to treat heart conditions, for example. All this hype, but one major obstacle stopping such therapies becoming more commonplace is efficiently producing large batches of cells to use. One potential solution to this is travelling 250 miles above us on the International Space Station. This unique lab allows astronauts to perform experiments in microgravity and these near-zero gravity conditions may hold the secret to rapid mass production of stem cells for regenerative medicine. Astronauts are also working on projects to engineer stem cell-derived products like cardiac tissue (pictured) and model diseases which could form a futuristic roadmap of biomanufacturing to bring us new ways to live healthier lives.

Written by Sophie Arthur

Image from work by Arun Sharma and colleagues

Collaborative - including Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, LA, CA; Center for the Advancement of Science in Space, Inc, Melbourne, FL; McGowan Institute for Regenerative Medicine, Pittsburgh, PA,USA

Image originally published with a Creative Commons Attribution 4.0 International (CC BY 4.0)

Published in Stem Cell Reports, December 2021

4th Internacional Congress Biomanufacturing Challenges of Inmunotherapy.

Center of Inmunology Molecular, CIM.

Hotel Meliá Las Dunas, Cayo Santa María, Villa Clara, Cuba

Vaccines CIMAher, CIMAvax EGF,

IOR Epocim

Engineers weigh in on 'smaller is better' chemical production

Ramon Gonzalez sees flares burning methane from the stacks above Houston's refineries and thinks, "What a waste." He believes that methane represents an opportunity for biomanufacturing that should not be missed.

The Rice University professor and director of its new Advanced Biomanufacturing Initiative, aka iBIO, already knows what an entire sector of the chemical manufacturing industry is beginning to realize: That waste methane can and should be turned into profit.

Given the steady advance of biomanufacturing—the use of wild-type or genetically modified bacteria to turn carbon-rich methane and other substances into valuable chemicals—it should be possible to produce chemicals on a smaller, more environmentally friendly scale, he said. But it would require a shift from current thinking that economic viability can come only from the economies of unit scale afforded by large facilities.

Biomanufacturing's promise is the subject of a perspective paper in Science this week by Gonzalez and his Rice colleagues, senior research scientist James Clomburg and graduate student Anna Crumbley.

The Regenerative Medicine Market is on the cusp of a "biological renaissance" that will redefine the boundaries of human potential over the next decade. By 2033, we will likely see the full realization of "Synthetic Biology" in clinical practice, where cells are designed from scratch to perform specific therapeutic functions. These "designer cells" could be programmed to seek out and destroy cancer cells, clear arterial plaques, or even release precise doses of insulin in response to blood sugar levels. This move toward "living medicines" represents a fundamental departure from the static chemical drugs of the past, creating a dynamic and responsive form of healthcare that adapts to the patient's changing needs in real-time.

Organ-on-a-chip technology will also reach its zenith, allowing for the rapid testing of new regenerative therapies without the need for animal or human subjects in the early stages. This will drastically accelerate the "bench-to-bedside" timeline, allowing new cures to reach the market in a fraction of the time it currently takes. Furthermore, the integration of nanotechnology will allow for the precision delivery of regenerative agents to specific parts of the body, such as the brain or the heart, with zero side effects on other organs. This "atomic-scale" precision is the key to unlocking the full potential of regenerative medicine, ensuring that the body’s healing power is directed exactly where it is needed most.

The concept of "In Situ" regeneration—where the body is stimulated to heal itself without the need for external cell transplants—will become a major market segment. By using specialized drug delivery systems and localized growth factors, clinicians will be able to "wake up" dormant stem cells within a patient's own tissue. This would simplify the treatment process and eliminate many of the logistical challenges associated with handling living cells. This approach would be particularly revolutionary for military medicine and emergency response, allowing for the rapid regeneration of tissues and bones in the field. The regenerative medicine market is moving toward a future where the body’s natural repair mechanisms are enhanced and controlled with clinical precision.

The strategic importance of these high-tech shifts is perfectly illustrated by the trajectory of the Regenerative Medicine Market. The Regenerative Medicine Market was valued at USD 40.98 Billion in 2025 and is projected to grow to USD 205.12 Billion by 2033, with a compound annual growth rate (CAGR) of 22.30% from 2027 to 2033. This growth is anchored by a global commitment to "Biomanufacturing 4.0," which seeks to apply the principles of the digital revolution to the production of living therapies, ensuring that the regenerative solutions of 2033 are as reliable and scalable as the semiconductors of today.

Market Overview According to Metastat Insight-style structured analysis, the global synthetic biology market is valued at USD 19.5 billion in 2025 and is projected to reach USD 59.7 billion by 2032, exhibiting a CAGR of 17.3% during the forecast period. Gene Synthesis accounts for nearly 29.7% of market revenues, driving innovation and expanding applications through intense research. The market is evolving from laboratory experimentation to widespread industrial adoption, reshaping sectors like healthcare, agriculture, and energy with sustainable, bio-based solutions.

Major Players Profiled in the Market Report: • Agilent Technologies • Amyris, Inc. • Arzeda Corporation • Codexis, Inc. • GenScript Biotech Corporation • Ginkgo Bioworks • Inscripta, Inc. • LanzaTech • Merck KGaA • New England Biolabs, Inc. • Precigen, Inc. • Synbio Technologies LLC • Synlogic, Inc. • Synthego Corporation • Thermo Fisher Scientific, Inc. • Twist Bioscience Corporation

Segments

Gene Synthesis Leading Technological Advancements By Technology, the market is divided into Gene Synthesis, Genome Engineering, Sequencing, Bioinformatics, Site-directed Mutagenesis, Cloning, Measurement and Modelling, and Others. Gene Synthesis dominates due to its crucial role in creating customized DNA constructs for novel therapeutics and industrial bio-production. Genome Engineering and Sequencing are also pivotal, enabling precision editing and rapid diagnostic capabilities.

Tools for Biological Construction By Tool, the market is segmented into Oligonucleotide/Oligo Pools and Synthetic DNA, Enzymes, Cloning Technologies Kits, Xeno-Nucleic Acids, and Chassis Organism. Oligonucleotides and Synthetic DNA are fundamental for genetic design, while engineered Enzymes serve as catalysts for specific biochemical reactions. Cloning Kits facilitate accessible innovation, bridging research and industrial applications.

Transforming Applications Across Industries By Application, the market is categorized into Pharmaceutical and Therapeutics, Industrial Biotechnology, Agriculture and Food Technology, Environmental Applications, Healthcare and Diagnostics, and Others. The Pharmaceutical sector leads with engineered biologics and personalized treatments. Industrial Biotechnology is advancing renewable fuels and chemicals, while Agriculture focuses on sustainable crop enhancement and food security.

Report Coverage The report offers: • Major growth drivers, restraints, opportunities, and challenges • Comprehensive regional insights • List of key industry players • Key strategies such as product innovation, strategic partnerships, and M&A • Analysis of trends across all submarkets and technology types

Source ; https://www.metastatinsight.com/report/synthetic-biology-market

Drivers & Restraints

Drivers

Demand for Sustainable Bio-Based Products The shift towards green alternatives to fossil fuels and plastics is a primary driver. Synthetic biology enables the mass production of biodegradable materials and clean energy, aligning with global sustainability goals.

Advancements in Genetic Engineering Continuous improvements in gene editing technologies like CRISPR and automated DNA synthesis are accelerating innovation. These tools enhance precision and scalability, making synthetic biology solutions more viable for commercial use.

Restraints

High R&D Costs Significant financial investment is required for research facilities and technology, which can hinder smaller firms. Long development timelines and costly trials pose barriers to rapid market entry.

Ethical and Regulatory Challenges Concerns over biosafety, biosecurity, and the ethics of genetic modification lead to strict regulations. Navigating these complex legal frameworks is essential for market acceptance and growth.

Opportunities

Expansion in Healthcare & Pharmaceuticals There is immense potential in developing novel therapies, vaccines, and personalized medicines. Engineered microbes for faster drug discovery and disease treatment offer new avenues for healthcare innovation.

Investments in Biofuels & Renewable Resources Rising focus on renewable energy presents opportunities for synthetic biology to optimize biofuel production, reducing carbon footprints and dependence on traditional energy sources.

Regional Insights

North America A dominant market driven by strong R&D infrastructure, significant investment in biotechnology, and early adoption of advanced genetic tools in the U.S. and Canada.

Europe Focuses on sustainable manufacturing and healthcare applications, supported by favorable government policies and a robust pharmaceutical sector in Germany, the UK, and France.

Asia-Pacific The fastest-growing region, fueled by increasing government funding, rising demand for bio-based products, and expanding healthcare needs in China, India, and Japan.

South America Brazil and Argentina show potential in agricultural biotechnology and bioenergy applications.

Middle East & Africa Emerging interest in sustainable food and energy solutions, with investments in biotechnology research growing in GCC countries and South Africa.

Competitive Landscape The market features a mix of multinational giants and innovative startups. Companies are focused on: • Developing specialized platforms for DNA engineering (e.g., Ginkgo Bioworks, Twist Bioscience) • Enhancing precision in protein design and bio-production (e.g., Codexis, Amyris) • Expanding capabilities through strategic acquisitions and partnerships • Integrating automation and AI to accelerate product development • Addressing global challenges in health, energy, and sustainability through bio-engineered solutions